Digoxin: current clinical uses and management of toxicity

Released 19 June 2023     Expires: 19 June 2025      Programme: Digoxin 1 CPD/CME credit, 1 hour

Sponsorship Statement: This educational module has been solely funded by a grant from BTG Pharmaceuticals (a SERB company). BTG were not involved in the development of the programme, content, selection of authors or their arrangements. All content has been independently developed by OmniaMed Communications.

Digoxin is a medication commonly used in the treatment of heart failure and/or atrial fibrillation. This learning module is designed to give healthcare professionals (HCPs) involved in the management of patients with atrial fibrillation and/or congestive heart failure (cardiologists, geriatricians and other HCPs that manage the care of older persons, clinical pharmacists and GPs) an introduction to the current clinical use of digoxin. The module also reviews the pharmacology and mechanism of action of this cardiac glycoside. Overdose of digoxin may provoke troublesome arrhythmias or malignant hyperkalaemia. The module highlights the mechanism of digoxin toxicity, the important diagnostic aspects and outlines the various approaches to treatment depending on its acute or chronic nature.

BJC Learning - Digoxin

Learning objectives

After completing this module, participants should be better able to understand:

  • The use of digoxin in current heart failure management
  • The aetiology and pathophysiology of digoxin toxicity
  • The management of digoxin toxicity


Professor Andrew L Clark, Consultant Cardiologist and Chair of Clinical Cardiology at the
Hull University Teaching Hospitals NHS Trust
Dr Joseph Cuthbert, NIHR Academic Clinical Lecturer in Cardiology at the Hull York Medical School


1 CPD/CME credit, 1 hour
BJC Learning has assigned 1 hour of CPD/CME credit to this module


Use for revalidation – BJC Learning with reflection activity

This article can be used towards revalidation. If you would like to reflect on what you have learned, please log in or register to record your thoughts on how this article has influenced your practice.

One thought on “Digoxin: current clinical uses and management of toxicity”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.